Antiangiogenic Therapies in Endometriosis.
From: Department of Obstetrics and Gynaecology, San Martino Hospital and University of Genoa, Genoa, Italy. simone.ferrero@fastwebnet.it
British journal of pharmacology
- Publish Date: Sep 2006
- ISSN: 0007-1188
- Volume: 149
- Issue: 2
- Pages: 133-5
- Medium: Print
- Language: English
- Citation (JAMA): Ferrero S, Ragni N, Remorgida V, et al. Antiangiogenic Therapies in Endometriosis.. Br. J. Pharmacol. Sep 2006;149:133-5
Abstract
Oral contraceptives, androgenic agents, progestins and gonadotropin-releasing hormone analogues have all been successfully used in the treatment of endometriosis. However, none of these drugs can eradicate the disease. It is widely accepted that the growth of newly formed blood vessels is essential for the establishment and growth of endometriotic lesions; therefore, inhibition of angiogenesis may offer a new option for treatment of this disorder. In this paper, we reviewed anti-vascular endothelial growth factor agents and other angiostatic drugs (i.e., TNP470, endostatin, anginex, rapamycin) that have been studied in laboratory and animal models of endometriosis. Although preliminary results are interesting, further investigations are required before clinical trials can be planned in humans.
Mesh Headings (Keywords): Animals, Disease Models, Animal, Endometriosis, Female, Humans, Neovascularization, Pathologic
Check for Full Text / PubMed Unique Identifier (PMID): 16894342
This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.
Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.
The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.